Impact of GLP-1 Receptor Agonist Therapy on Alcohol Pharmacokinetics (TAP)

Inclusion Criteria:

• At least 21 years of age, no older than 55 years of age
• BMI 30-45 kg/m2
• Taking stable dose of prescribed, branded tirzepatide for at least 28 days
• Self-reported regular alcohol consumption
• Good mental health as determined by self-reported responses to the Psychopathology Screener and review by Study Physician as necessary
• Absence of any major medical, cardiovascular, endocrine, and neurological condition as determined by self-reported responses to the Medical History Screener
• In possession of a valid drivers' license with at least two years of driving experience
• English-speaking (able to provide consent and complete questionnaires)
• Written Informed Consent

Exclusion Criteria:

• AUDIT score of >8 requires Study Physician review
• Use of compounded GLP-1 RA
• History of or current substance use disorder as determined by self-reported responses to the Internalizing, Externalizing, and Substance Use Disorder Screener, Drug Use Disorders Identification Test, Alcohol Use Disorder Identification Test
• Pregnancy or lactation (pregnancy test, if needed)
• Use of medications that may impact cognitive ability or potentiate alcohol (e.g., mood stabilizers, sedatives)
• Use of medications that are known to significantly delay gastric emptying as determined by Study Physician
• History of pancreatitis, severe gastroparesis, or personal or family history of medullary thyroid or multiple endocrine neoplasia syndrome type 2